Paraskevi Farmaki, Christos Damaskos, Nikolaos Garmpis, Anna Garmpi, Spyridon Savvanis and Evangelos Diamantis* Pages 138 - 146 ( 9 )
Cardiovascular Disease (CVD) remains the leading cause of morbidity and mortality in the western world. Hypolipidemic drugs have long been used for the primary and secondary prevention of heart disease. However, the high frequency of recurrent events in patients despite hypolipidemic therapy has increased the need for new more targeted therapeutic approaches. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are monoclonal antibodies to the PCSK9 gene and represent a new class of drugs that have been shown to further decrease LDL-C when administered as a monotherapy or in combination with statins. In addition to LDL reduction, PCSK9 inhibitors are shown to decrease apolipoprotein B and lipoprotein (a) levels without major adverse effects. Whether or not PCSK9 inhibitors can actually reduce the incidence of cardiovascular events and ameliorate CVD prognosis is yet to be clarified. This review summarizes recent literature on the safety and efficacy of PCSK9 inhibitors on CVD outcome and its potential role in the management of patients with high-risk cardiovascular disease.
PCSK9, inhibitors, cardiovascular disease, hypolipidemic drugs, hypolipidemic therapy, PCSK9 inhibitors.
First Department of Pediatrics, Aghia Sophia Children's Hospital, Athens, Second Department of Propedeutic Surgery, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Second Department of Propedeutic Surgery, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Internal Medicine Department, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Department of Internal Medicine, General Hospital of Athens "Elpis", Athens, Department of Endocrinology, Diabetes and Metabolism, Evangelismos Hospital, Athens